Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 CA155258, P50 CA100707)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Veterans Affairs (5I01BX001584)
Celgene Corporation and Paula and Roger Riney Foundation.
Received: 16 October 2020
Accepted: 14 January 2021
First Online: 8 February 2021
: K.C.A. has received consulting fees from Bristol-Myers Squibb, Celgene, Gilead, Janssen, Precision Biosciences, Sanofi-Aventis, Takeda, and Tolero, and on the board of directors and stock options Oncopep. N.C.M. is a consultant for BMS, Janssen, Oncopep, Amgen, Karyopharm, Legened, Abbvie, Takeda, and GSK, and on the board of directors and stock options Oncopep. T.C., K.H., and S.K. are employed by Bristol-Myers Squibb. F.P. is employed by Bluebird Bio. Other authors declare no competing interests.